Blockchain Registration Transaction Record

Soligenix's ThermoVax Ebolavirus Vaccines Show 2-Year Stability at 40°C

Soligenix announces ebolavirus vaccines with ThermoVax platform remain potent after 2 years at 40°C, enhancing global distribution and pandemic readiness.

This development matters because thermostable vaccines eliminate the need for cold-chain storage, which is a major barrier to vaccine distribution in remote or resource-limited areas. By maintaining potency at high temperatures, these vaccines could drastically improve access to life-saving immunizations during outbreaks of deadly viruses like Ebola and Marburg, enhancing global pandemic preparedness and potentially saving countless lives in regions where refrigeration is unreliable or unavailable.